Skip to main content

Research Repository

Advanced Search

All Outputs (212)

Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study (2023)
Journal Article
Dicpinigaitis, P. V., Morice, A. H., Smith, J. A., Sher, M. R., Vaezi, M., Guilleminault, L., Niimi, A., Gude, K., Krahn, U., Saarinen, R., Pires, P. V., Wosnitza, M., & McGarvey, L. (2023). Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study. Lung, 201, Article 255-266. https://doi.org/10.1007/s00408-023-00621-x

Introduction: The PAGANINI study evaluated the efficacy and safety of the selective P2X3 antagonist eliapixant in patients with refractory chronic cough (RCC). Methods: PAGANINI was a randomized, double-blind, parallel-group, placebo-controlled, mult... Read More about Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study.

Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site (2023)
Journal Article
Crooks, M. G., Crowther, L., Cummings, H., Cohen, J., Huang, C., Pitel, L., Pearson, M., Morice, A., Turgoose, J., Faruqi, S., Watt, M., Morris, T., & Xu, Y. (2023). Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site. ERJ Open Research, 9(3), Article 00685-2022. https://doi.org/10.1183/23120541.00685-2022

Aim: Short-acting β2-agonist (SABA) overuse adversely impacts asthma-related outcomes and the environment. The SABA rEductioN Through ImplemeNting Hull asthma guidELines (SENTINEL) programme aims to reduce SABA overuse through supported implementatio... Read More about Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site.

Subcutaneous octreotide as a therapeutic option for refractory chronic cough: subjective response pattern and adverse effects from a retrospective single-centre case series (2023)
Journal Article
Brindle, K., Zhang, M., Carter, N., & Morice, A. H. (2023). Subcutaneous octreotide as a therapeutic option for refractory chronic cough: subjective response pattern and adverse effects from a retrospective single-centre case series. ERJ Open Research, 9(3), Article 00100-2023. https://doi.org/10.1183/23120541.00100-2023

The “vicious circle” of chronic cough: The patient experience – qualitative synthesis (2023)
Journal Article
Brindle, K., Morice, A., Carter, N., Sykes, D., Zhang, M., & Hilton, A. (2023). The “vicious circle” of chronic cough: The patient experience – qualitative synthesis. ERJ Open Research, 9(3), Article 00094-2023. https://doi.org/10.1183/23120541.00094-2023

Aim The aim of this study was to systematically search and synthesise findings from peer-reviewed qualitative studies describing the experiences of those living with chronic cough. Methods A systematic search was conducted to identify all studies tha... Read More about The “vicious circle” of chronic cough: The patient experience – qualitative synthesis.

The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial (2023)
Journal Article
Friedrich, C., Francke, K., Birring, S. S., van den Berg, J. W. K., Marsden, P. A., McGarvey, L., Turner, A. M., Wielders, P., Gashaw, I., Klein, S., & Morice, A. H. (2023). The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial. Respiratory Research, 24(1), Article 109. https://doi.org/10.1186/s12931-023-02384-8

BACKGROUND: P2X3 receptor antagonists seem to have a promising potential for treating patients with refractory chronic cough. In this double-blind, randomized, placebo-controlled study, we investigated the efficacy, safety, and tolerability of the no... Read More about The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial.

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks (2023)
Journal Article
Birring, S. S., Dicpinigaitis, P. V., Smith, J. A., Morice, A. H., McGarvey, L. P., Pavord, I. D., Nguyen, A. M., Schelfhout, J., Li, Q., Iskold, B., Green, S. A., Philip, G., Muccino, D. R., & La Rosa, C. (2023). Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks. American Journal of Respiratory and Critical Care Medicine, 207(11), 1539-1542. https://doi.org/10.1164/rccm.202211-2128LE

Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies (2023)
Journal Article
Stinson, R. J., Morice, A. H., & Sadofsky, L. R. (2023). Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies. Respiratory Research, 24(1), Article 45. https://doi.org/10.1186/s12931-023-02347-z

Background: Upper respiratory tract infections (URTIs) impact all age groups and have a significant economic and social burden on society, worldwide. Most URTIs are mild and self-limiting, but due to the wide range of possible causative agents, inclu... Read More about Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies.

Ingredients of Vicks VapoRub inhibit rhinovirus-induced ATP release (2023)
Journal Article
Stinson, R. J., Morice, A. H., Ahmad, B., & Sadofsky, L. R. (2023). Ingredients of Vicks VapoRub inhibit rhinovirus-induced ATP release. Drugs in Context, 12, 1-18. https://doi.org/10.7573/dic.2023-3-2

Background: Over-the-counter therapies, such as Vicks VapoRub, are frequently used in the management of upper respiratory tract infection symptoms. Of these, acute cough is the most bothersome; however, the mechanisms involved have not been fully elu... Read More about Ingredients of Vicks VapoRub inhibit rhinovirus-induced ATP release.

Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study (2023)
Journal Article
Zhang, M., Morice, A. H., Si, F., Zhang, L., Chen, Q., Wang, S., Zhu, Y., Xu, X., Yu, L., & Qiu, Z. (2023). Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study. Therapeutic Advances in Respiratory Disease, 17, https://doi.org/10.1177/17534666231167716

BACKGROUND: The management of refractory chronic cough (RCC) is a great challenge. Neuromodulators have long been used for RCC with imperfect efficacy. OBJECTIVES: We summarized the outcomes of the current treatments used at our specialist cough clin... Read More about Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study.

Chronic cough—the limitation and advances in assessment techniques (2022)
Journal Article
Zhang, M., Sykes, D. L., Brindle, K., Sadofsky, L. R., & Morice, A. H. (2022). Chronic cough—the limitation and advances in assessment techniques. Journal of thoracic disease, 14(12), 5097-5119. https://doi.org/10.21037/jtd-22-874

Accurate and consistent assessments of cough are essential to advance the understanding of the mechanisms of cough and individualised the management of patients. Considerable progress has been made in this work. Here we reviewed the currently availab... Read More about Chronic cough—the limitation and advances in assessment techniques.

Nebivolol as a Potent TRPM8 Channel Blocker: A Drug-Screening Approach through Automated Patch Clamping and Ligand-Based Virtual Screening (2022)
Journal Article
Jahanfar, F., Sadofsky, L., Morice, A., & D’Amico, M. (2022). Nebivolol as a Potent TRPM8 Channel Blocker: A Drug-Screening Approach through Automated Patch Clamping and Ligand-Based Virtual Screening. Membranes, 12(10), Article 954. https://doi.org/10.3390/membranes12100954

Transient Receptor Potential Melastatin 8 (TRPM8) from the melastatin TRP channel subfamily is a non-selective Ca2+-permeable ion channel with multimodal gating which can be activated by low temperatures and cooling compounds, such as menthol and ici... Read More about Nebivolol as a Potent TRPM8 Channel Blocker: A Drug-Screening Approach through Automated Patch Clamping and Ligand-Based Virtual Screening.

Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms (2022)
Journal Article
Sykes, D. L., Crooks, M. G., Hart, S. P., Jackson, W., Gallagher, J., & Morice, A. H. (2022). Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms. Respiratory medicine, 202, Article 106985. https://doi.org/10.1016/j.rmed.2022.106985

Background: The interaction between the respiratory and gastrointestinal systems, and the role of the latter in the development of respiratory pathology, has been examined with a focus on gastro-oesophageal reflux disease (GORD). However, little data... Read More about Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms.

Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups (2022)
Journal Article
Smith, J. A., Birring, S. S., Dicpinigaitis, P. V., McGarvey, L. P., Morice, A. H., Pavord, I. D., Satia, I., Green, S., Iskold, B., La Rosa, C., Li, Q., Martin Nguyen, A., Schelfhout, J., & Muccino, D. (2022). Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups. Lung, 200(4), 423-429. https://doi.org/10.1007/s00408-022-00553-y

Introduction: In phase 3 trials (COUGH-1/COUGH-2), gefapixant 45 mg twice daily significantly reduced 24-h cough frequency vs placebo in refractory or unexplained chronic cough (RCC or UCC). Methods: Here, the efficacy of gefapixant 45 mg vs placebo... Read More about Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.

ATP, an attractive target for the treatment of refractory chronic cough (2022)
Journal Article
Zhang, M., Sykes, D. L., Sadofsky, L. R., & Morice, A. H. (2022). ATP, an attractive target for the treatment of refractory chronic cough. Purinergic Signalling, 18, 289-305. https://doi.org/10.1007/s11302-022-09877-z

Chronic cough is the most common complaint in respiratory clinics. Most of them have identifiable causes and some may respond to common disease-modifying therapies. However, there are many patients whose cough lacks effective aetiologically targeted... Read More about ATP, an attractive target for the treatment of refractory chronic cough.

Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study (2022)
Journal Article
Friedrich, C., Francke, K., Gashaw, I., Scheerans, C., Klein, S., Fels, L., Smith, J. A., Hummel, T., & Morice, A. (2022). Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study. Clinical Pharmacokinetics, 61, 1143–1156. https://doi.org/10.1007/s40262-022-01126-1

Background and Objective: There is no licensed treatment for refractory chronic cough; off-label therapies have limited efficacy and can produce adverse effects. Excessive adenosine triphosphate signaling via P2X3 receptors is implicated in refractor... Read More about Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.

Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough (2022)
Journal Article
Dicpinigaitis, P. V., Birring, S. S., Blaiss, M., McGarvey, L. P., Morice, A. H., Pavord, I. D., Satia, I., Smith, J. A., La Rosa, C., Li, Q., Nguyen, A. M., Schelfhout, J., Tzontcheva, A., & Muccino, D. (2023). Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. Annals of Allergy, Asthma and Immunology, 130(1), 60-66. https://doi.org/10.1016/j.anai.2022.05.003

Background: The current characterization of patients with refractory or unexplained chronic cough (RCC and UCC, respectively) primarily stems from relatively small clinical studies. Objective: To report the baseline medical history and clinical chara... Read More about Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough.

Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS) (2022)
Journal Article
Cotton, S., Devereux, G., Abbas, H., Briggs, A., Campbell, K., Chaudhuri, R., Choudhury, G., Dawson, D., De Soyza, A., Fielding, S., Gompertz, S., Haughney, J., Lang, C. C., Lee, A. J., MacLennan, G., MacNee, W., McCormack, K., McMeekin, N., Mills, N. L., Morice, A., …Lipworth, B. J. (2022). Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 23(1), Article 307. https://doi.org/10.1186/s13063-022-06226-8

Background: Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs. Beta blockers are well-established drugs widely used to treat cardiovascular conditions. Observational studies consiste... Read More about Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).

Treatment of chronic cough: P2X3 receptor antagonists and beyond (2022)
Journal Article
Sykes, D. L., Zhang, M., & Morice, A. H. (2022). Treatment of chronic cough: P2X3 receptor antagonists and beyond. Pharmacology and Therapeutics, 237, Article 108166. https://doi.org/10.1016/j.pharmthera.2022.108166

For years chronic cough (CC) has presented an enormous physical, psychological, and social burden on those who experience it, with no approved pharmacological therapies to assuage their symptoms. With our improved understanding of the pathophysiologi... Read More about Treatment of chronic cough: P2X3 receptor antagonists and beyond.